Telomerase inhibition as an adjuvant anticancer therapy: It is more than just a waiting game

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 4, 2007, Pages 427-430

  Elmore, Lynne W ^a   Holt, Shawn E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; Alternative lengthening of telomeres; Cancer; Chemotherapy; Telomerase; Telomere

Indexed keywords

CYTOTOXIC AGENT; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE;

CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GROWTH; CELL DIVISION; CYTOTOXICITY; DRUG MECHANISM; DYNAMICS; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SPECIFICITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PROTEIN EXPRESSION; REGULATORY MECHANISM; TELOMERE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE;

EID: 33947643146     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.4.427     Document Type: Editorial

References (16)

1. KIM NW, PIATYSZEK MA, PROWSE KR et al: Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 266:2011-2015.
2. SHAY JW, BACCHETTI S: A survey of telomerase activity in human cancer. Science (1997) 33:787-791.
3. FLORES I, BENETTI R, BLASCO MA: Telomerase regulation and stem cell behavior. Curr. Opin. Cell Biol. (2006) 18(3):254-260.
4. MASUTOMI K, POSSEMATO R, WONG JM et al: The telomerase reverse transcriptase regulates chromatin state and DNA damage response. Proc. Natl. Acad. Sci. USA (2005) 102(23):8222-8227.
5. MASUTOMI K, YU EY, KHURTS S et al: Telomerase maintains telomere structure in normal human cells. Cell (2002) 114:241-253.
6. TAM W-L, ANG Y-S, LIM B: The molecular basis of ageing in stem cells. Mech. Ageing. Dev. (2007) 128:137-148.
7. EPEL ES, BLACKBURN EH, LIN J et al: Accelerated telomere shortening in response to life stress. Proc. Natl. Acad. Sci. USA (2004) 101(49):17312-17315.
8. HARRINGTON LA, GREIDER CW: Telomerase primer specificity and chromosome healing. Nature (1991) 353:451-454.
9. YU G-L, BLACKBURN EH: Developmentally programmed healing of chromosomes by telomerase in Tetrahymena. Cell (1991) 67:823-832.
10. MERGNY J-L, RIOU J-F, MAILLIET P et al: Summary and Survey: Natural and pharmacologic regulation of telomerase. Nuclei Acids Res. (2002) 30(4):839-865.
11. CERONE MA, LONDONO-VALLEJO JA, AUTEXIER C: Telomeres inhibition enhances the response to anti-cancer drug treatment in human breast cancer cells. Mol. Cancer Ther. (2006) 5(7):1669-1675.
12. CERONE MA, LONDONO-VALLEJO JA, AUTEXIER C: Mutated telomeres sensitize tumor cells to anti-cancer drugs independent of telomere shortening and mechanisms of telomere maintenance. Oncogene (2006) 25(56):7411-7420.
13. ZHANG XL, MAR V, ZHOU W, HARRINGTON, L, ROBINSON MA: Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. (1999) 13:2388-2399.
14. BECHTER OE, ZOU Y, WALKER W, WRIGHT WE, SHAY JW: Telomeric recombination in mismatch repair deficient colon cancer cells after telomere inhibition. Cancer Res. (2004) 64(10):3444-3451.
15. CHANG S, KHOO CM, NAYLOR ML, MASER RS, DEPINHO RA: Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev. (2003) 17:88-100.
16. HERBERT BS, PITTS AE, BAKER SI et al: Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA (1999) 96:14276-14281.